Kornimate/medical-research-clean huggingface dataset:
impact of medical emergency team and ems in tampere university hospital

Conditions: Death, Sudden,Cardiac

Summary: patients in general wards have abnormal physical values preceding in-hospital cardiac arrest or a transfer to intensive care unit (icu). the purpose of medical emergency team (met) or ems is to interfere early enough in deteriorating patient status to prevent adverse outcomes like cardiac arrest or transfer to intensive care unit. the aims of this study are to record and analyze the effects of ems and department of emergency and both afferent and efferent limbs of met activity in finnish tertiary hospital.


Eligibility criteria:
inclusion criteria: * 18 yrs or older exclusion criteria: * under 18 yrs

Keywords: met
early emdr following covid-19 critical illness: a feasibility trial

Conditions: Post Traumatic Stress Disorder; Intensive Care Psychiatric Disorder; Anxiety Disorders; Depression; Critical Care; COVID

Summary: primary objective is to evaluate the feasibility of delivering an online early eye movement desensitisation reprocessing (emdr) recent traumatic events protocol (r-tep) to patients who have survived covid-19 related critical illness, within the context of a randomised controlled trial (rct). this will inform the design of a future rct investigating the effectiveness of emdr r-tep in reducing psychological symptoms, for adult survivors of intensive care.

a significant number of patients worldwide, have been admitted to intensive care suffering from covid-19 related organ failure. patients who survive a period of critical illness have a disproportionately high chance of suffering from significant and persistant poor psychological outcomes. eye-movement desensitisation and reprocessing (emdr) has reduced incidence of psychological morbidity in war veterans and victims of man-made and natural disasters. small studies have also shown it to be effective in healthcare settings, within the emergency department, following cancer diagnosis and implantation of cardioverter defibrillators. emdr is validated by uk national institute of clinical excellence guidance for use in treating adult onset ptsd. because of ongoing social distancing guidance our study programme aims to investigate whether it is feasible to treat patients with an early online eye movement desensitisation reprocessing (emdr) intervention, delivered soon after hospital discharge and whether this intervention will improve psychological outcome for survivors of critical illness.

Eligibility criteria:
inclusion criteria: * acute admission to critical care who have required mechanical ventilation for at least 24 hours * pcr confirmed covid-19 positive * \>18 years of age * capacity to provide informed consent exclusion criteria: * acute brain injury * cognitive impairment * pre-existing psychotic diagnosis * not expected to survive post-hospital discharge * refusal to grant consent

Keywords: emdr eye movement desensitisation and reprocessing
n.i.s of ait in adult patients with house dust mite allergy in real practice in france

Conditions: Allergic Rhinitis Due to House Dust Mite; Allergic Asthma Due to Dermatophagoides Farinae; Allergic Asthma Due to Dermatophagoides Pteronyssinus

Summary: non-interventional study to investigate the safety and tolerability of allergy immunotherapy acarizax® 12 sq-hdm in real-life clinical practice in adults patients (\>18 years) with house dust mite allergy over a period of 12 months.

condition: * persistent moderate to severe hdm allergic rhinitis despite use of symptom-relieving medication * hdm allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe hdm allergic rhinitis. patients' asthma status should be carefully evaluated before the initiation of treatment.

Eligibility criteria:
inclusion criteria: * at the discretion of the investigator, patient who will be prescribed acarizax® in line with the approved summary of product characteristics (smpc) and who have been informed, after explicit written explanation and willing to participate in the study by signed consent exclusion criteria: * patient who did not have 12 months prior inclusion or have an on-going, house dust mite (hdm) allergy immunotherapy (ait).

Keywords: allergy allergic rhinitis allergic asthma house dust mite immunotherapy
evaluation of renal pretransplant serology for bk virus on the risk of post-transplant viral reactivation

Conditions: BK Virus Nephropathy; Risk Factor; Kidney Transplantation

Summary: due to the increasing importance of bkv infection on the survival of kidney transplants, a better knowledge, in the pretransplant phase, of the risk factors leading to viral reactivation could allow the follow-up physician to be more vigilant and better prevent this pathology. there are no commercial tests for bkv serology. in the virology laboratory, the investigators have developed the technique for producing "virus-like particles" (vlp) that mimics the antigenic structure of the bk virus. the investigators plan to evaluate seroreactivity to the five bk virus serotypes in the recipient of a kidney transplant as a pretransplant and to compare this data with the detection or not of viral reactivation in the recipient during the first post-transplant year.


Eligibility criteria:
inclusion criteria: * adult kidney transplanted patients * renal transplant patients with regular virological follow-up (blood and urine for bkv) during the first year after transplantation. exclusion criteria: * renal transplant patients with no follow-up for one year after transplantation (transplant failure, return to dialysis, death, follow-up outside the transplant centre)

Keywords: bk virus nephropathy risk factor kidney transplantation viral serology
study evaluating etanercept on skin and joint disease in psoriatic arthritis

Conditions: Psoriatic Arthritis

Summary: the purpose of the study was to compare the efficacy of 2 different etanercept regimens for the treatment of skin and joint manifestations of psoriatic arthritis.


Eligibility criteria:
inclusion criteria: inclusion criteria: * 18 years of age or older at time of consent * active psoriatic arthritis * clinically stable, plaque psoriasis involving more than 10% of the body surface area exclusion criteria: exclusion criteria: * evidence of skin conditions other than psoriasis that would interfere with skin examinations. * systemic anti-psoriasis therapy or dmard within 28 days of study drug initiation * prior exposure to any tnf-inhibitor, including etanercept

Keywords: psoriatic arthritis skin disease joint disease
clinical and laboratory characteristics of sickle cell anemia patients admitted with fever

Conditions: Sickle Cell Anemia; Sickle Cell Thalassemia

Summary: this study will summarized the clinical and laboratory data and the outcome of all the patients suffering from sickle cell anemia (including sickle cell thalassemia) admitted to the pediatric ward.

the actual protocol for sca patients admitted with fever is to obtain blood cultures and start empiric antibiotic treatment. the study cohort included 60 sca patients actually treated in the pediatric hematology unit.

Eligibility criteria:
inclusion criteria: all patients admitted with fever as the only presenting symptom. exclusion criteria: patients admitted with another causes related or unrelated to sickle cell disease and have also fever.

Keywords: fever blood cultures
swog-9430: surgery in treating patients with metastatic melanoma

Conditions: Melanoma (Skin)

Summary: rationale: surgery may be effective therapy in treating patients with metastatic melanoma. purpose: this phase ii trial is studying how well surgery works in treating patients with metastatic melanoma.

objectives: * assess overall and progression-free survival in patients with metastatic melanoma (beyond the draining lymph nodes) after complete surgical resection of all known disease. * determine the ability of the southwest oncology group melanoma committee to enroll patients with metastatic melanoma who can be resected to a disease-free state. outline: this is a multicenter study. all patients undergo gross total resection of all known disease. patients whose disease cannot be completely resected or who have disease recurrence after surgery are removed from study. patients found to have microscopic residual disease after surgery are considered completely resected. resected tissue is submitted for analysis on protocol swog-9431. patients may receive any adjuvant therapy (e.g., radiotherapy, interferon, and/or vaccines) deemed clinically appropriate by the treating physician. patients are followed periodically for 5 years after study entry. projected accrual: a total of 100 eligible patients with completely surgically resected disease will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed metastatic melanoma that is deemed grossly surgically resectable * multiple resected sites or metastatic melanoma of unknown primary allowed provided all known disease can be grossly resected * recurrence in iliac lymph nodes after inguinal lymph dissection allowed * no metastatic disease beyond the lesions planned for resection * confirmed by ct scan of chest, abdomen, pelvis, and ct or mri of brain within 42 days of study * concurrent registration on protocol swog-9431 required patient characteristics: age: * 18 and over performance status: * swog 0-2 hematopoietic: * not specified hepatic: * not specified renal: * not specified other: * no other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage i or ii cancer from which patient is currently disease free * not pregnant prior concurrent therapy: biologic therapy: * prior immunotherapy in the adjuvant or metastatic setting allowed chemotherapy: * prior chemotherapy in the adjuvant or metastatic setting allowed endocrine therapy: * prior hormonal therapy in the adjuvant or metastatic setting allowed radiotherapy: * prior radiotherapy in the adjuvant or metastatic setting allowed surgery: * see disease characteristics * at least 14 days since prior surgery in the adjuvant or metastatic setting other: * recovered from prior therapy

Keywords: stage iv melanoma recurrent melanoma
structural and functional networks in als: an insight into pseudobulbar affect

Conditions: Amyotrophic Lateral Sclerosis; Pseudobulbar Affect

Summary: the investigators aim to elucidate characteristics of structural and functional brain connectivity in patients with amyotrophic lateral sclerosis (als) and pseudobulbar affect (pba) using diffusion kurtosis imaging (dki) and magnetoencephalography (meg).


Eligibility criteria:
inclusion criteria: * diagnosed with als in the last 6 months according to gold coast criteria exclusion criteria: * - lack of ability to answer survey through own ability or through a surrogate, for example by hand controlled, eye-controlled computer and/or tablet, or through telephone interview. * lack of ability to cooperate. * pregnancy * drug addiction defined as the non-prescribed use of cannabis, opioids, or other narcotics. * alcohol addiction defined as over 21 units weekly. * lesional neurological diseases, such as stroke, tumor or multiple sclerosis * epilepsy * neurodegenerative diseases other than als * severe psychiatric disease such as major depression disorder, bipolar disease or schizophrenia * contraindication for mri and meg scan according to hospital guidelines * severe liver or kidney disease * dysregulated heart disease * ongoing treatment with any antidepressants or any antipsychotics at recruitment. * diagnosed with frontotemporal dementia.

Keywords: diffusion kurtosis imaging magnetoencephalography connectivity
metabolism evaluation through resting indirect calorimetry in bladder cancer (metrics)

Conditions: Bladder Cancer

Summary: this study is being done to learn more about energy needs and muscle function during treatment for bladder cancer. these insights can help improve future patient care. the study team found in a previous study that resting energy can be different than what estimates show. patients with bladder cancer are known to suffer a decline in physical resilience over time. monitoring patients to understand these changes better could help design future treatments with these vulnerabilities in mind.

the investigators' long-term goal is to improve cachexia treatment for patients with cancer. the project is significant because identifying cachexia earlier in its onset allows for earlier and more successful treatment. major barriers to early detection and treatment are: 1) clear specific lab tests to confirm the diagnosis and 2) identifying when resting energy expenditure (ree) increases. it is the investigators' expectation that at the completion of these descriptive studies, key factors will be identified to guide earlier detection and treatment of cachexia. platinum-based chemotherapy and surgery are a dual-phase treatment regimen to treat bladder cancer that has a high risk of worsening cachexia compared to other cancer types not requiring such an intensive treatment regimen. inhibition of growth differentiation factor 15 (gdf-15) is a promising preventive strategy against cachexia in patients with bladder cancer. understanding gdf-15 and ree changes over the course of treatment could inform proactive rather than reactive strategies to support the health of these patients and translate to patients with other types of cancer. the objective of this application is to assess changes in gdf-15 and ree levels during the treatment course for advanced bladder cancer.

Eligibility criteria:
inclusion criteria: * confirmed cancer diagnosis * scheduled for platinum-based chemotherapy followed by radical cystectomy * adequate renal and cardiac function for platinum-based chemotherapy exclusion criteria: * prior chemotherapy or radiotherapy for bladder cancer * severe cardiac, renal, hepatic, respiratory or metabolic diseases * pregnant or breastfeeding * uncontrolled conditions that could affect study outcomes

Keywords: bladder cancer resting energy expenditure cachexia growth differentiation factor 15 (gdf-15) nutrition status radical cystectomy neoadjuvant chemotherapy body composition
n-3 polyunsaturated fatty acids in obesity

Conditions: Adipose Tissue Inflammation; Morbid Obesity

Summary: inflammation in the adipose (fat) tissue is an important condition leading to metabolic derangements and cardiovascular disease in obese patients. n-3 polyunsaturated fatty acids exert anti-inflammatory effects and prevent adipose tissue inflammation in rodent obesity. this study tests the hypothesis that n-3 polyunsaturated fatty acids ameliorate adipose tissue inflammation in morbidly obese patients.


Eligibility criteria:
inclusion criteria: * non-diabetic morbidly obese patients (bmi \> 40 kg/m2) supposed to undergo bariatric surgery * age 20-65 yrs exclusion criteria: * acute illness within the last two week * known diabetes mellitus or current anti-diabetic medication * acquired immunodeficiency (hiv infection) * hepatitis or other significant liver disease * severe or untreated cardiovascular, renal, pulmonary disease * untreated or inadequately treated clinically significant thyroid disease * anemia * active malignant disease * inborn or acquired bleeding disorder including warfarin treatment * pregnancy or breast feeding * drug intolerability that prohibits the use of the study drug
light therapy intervention in individuals with parkinson's disease

Conditions: Parkinson Disease

Summary: the study looks to investigate the effects that light therapy delivered to the frontal cortex could have on parkinson's disease related symptoms ( both cognitive and motor). the therapy is a non invasive technique that deliverers low level wavelength light to the front part of the head for 12 minutes. for this study the therapy will be done 3 times a week for 6 weeks. to measure the potential effects on the therapy in parkinson symptoms, we will do a set of cognitive and motor test before and after the intervention to measure any changes as well as control for any potential markers such as age, sex, disease level, medication and exercise.


Eligibility criteria:
inclusion criteria: * diagnosis of parkinson disease exclusion criteria: 1. participants who are unable to comply with study visit/testing requirements (e.g. participants who cannot go off pd medication for the pre-, post-, and 3-month assessments). 2. participants who are unable to provide consent. 3. participants with a deep brain stimulation (dbs) device. 4. participants who have a history of a psychiatric disorder 5. participants with pd who have other concurrent movement/neurological conditions, including dystonia, dementia, epilepsy etc. 6. participants with a clinical diagnosis of pd that is not considered primary (e.g. vascular parkinsonism) or participants where an atypical form of parkinsonism is suspected (e.g., progressive supranuclear palsy, multiple system atrophy). 7. participants with a history of cancer (whether treated with chemotherapy and/or radiotherapy or not). 8. participants with a history of a recent concussion or any facial, neck, or head injury within the last 6 months. ud irb approved: 03/12/2025 irbnet id#: 2277769-2 i/c from rev. 01/2024 page 3 of 10 participant's initial's ________ 9. known injury or disease that might interfere with motor function in the proposed experiments (e.g., stroke, traumatic brain injury, extrapyramidal dysfunction, neuromuscular disease, orthopedic problems that impair movement). 10. participants with a history of photosensitivity. 11. participants who are not able to walk unassisted for 2 minutes
radiation therapy plus hyperbaric oxygen in treating patients with newly diagnosed glioblastoma multiforme

Conditions: Brain and Central Nervous System Tumors

Summary: rationale: radiation therapy uses high-energy x-rays to damage tumor cells. hyperbaric oxygen may increase the effectiveness of radiation therapy. combining hyperbaric oxygen with radiation therapy may be an effective treatment for glioblastoma multiforme. purpose: phase i/ii trial to study the effectiveness of combining radiation therapy with hyperbaric oxygen in treating patients who have newly diagnosed glioblastoma multiforme.

objectives: i. determine the feasibility and toxicity of hyperbaric oxygen combined with conformal radiotherapy in patients with newly diagnosed glioblastoma multiforme. ii. determine the efficacy of this regimen in terms of radiographic tumor response, time to tumor progression, and survival in these patients. outline: within 2 weeks after surgery, patients receive hyperbaric oxygen over 90 minutes once daily, followed by conformal radiotherapy twice daily 5 days a week for 17 days in the absence of unacceptable toxicity. patients are followed within 2 weeks and then every 2 months thereafter. projected accrual: a total of 5-10 patients will be accrued for this study within 1 year.

Eligibility criteria:
disease characteristics: histologically proven newly diagnosed glioblastoma multiforme measurable residual tumor by mri after biopsy or craniotomy patient characteristics: age: over 18 performance status: karnofsky 70-100% life expectancy: more than 8 weeks hematopoietic: not specified hepatic: not specified renal: not specified pulmonary: no severe pulmonary disease (e.g., emphysema with carbon dioxide retention) no untreated pneumothorax other: not pregnant or nursing negative pregnancy test fertile patients must use effective contraception no other malignancy within the past 5 years except epithelial skin cancer no psychological, familial, sociological, or geographical conditions that would preclude study no intractable seizure disorder prior concurrent therapy: biologic therapy: not specified chemotherapy: no prior or concurrent bleomycin endocrine therapy: not specified radiotherapy: no prior cranial radiotherapy surgery: see disease characteristics other: no other prior therapy, including adjuvant therapy, for glioblastoma multiforme

Keywords: adult glioblastoma adult giant cell glioblastoma adult gliosarcoma
multiomics after headache provocation of people who are unable to have headache

Conditions: Headache; Healthy

Summary: headaches are extremely common illnesses with a combined lifetime prevalence of 90-99% in europe. despite this high prevalence, there are persons who have never, in their whole life, encountered a headache. the aim of the study is to identify factors that protect against headache by studying multiomics in people who never have had a headache (headache resistant) versus non-resistant controls. the investigators will measure multiomic changes (transcriptomics and metabolomics) after headache provocation with isosorbide mononitrate. 3 blood samples, two for rna and one for metabolomics are taken right before administration of isosorbide mononitrate, 3 hours after administration of isosorbide mononitrate and again 5 hours after administration of isosorbide mononitrate. the investigators hope to contribute with novelty to the current understanding of headache pathophysiology and development of more efficient treatment of headache.


Eligibility criteria:
inclusion criteria: * headache resistant and non-resistant male participants from the danish blood donor study. * weight: 45 kg to 95 kg exclusion criteria: * daily consumption of any medication. * consumption of any medication less than 12 hours prior to the study day. * headache on the study day or 48 hours prior to the study day. * amnestic or clinical signs of hypertension (systolic blood pressure \>150 mmhg and/or diastolic blood pressure \>100 mmhg) or hypotension (systolic blood pressure \<90 mmhg and/or diastolic blood pressure \<50 mmhg). * any severe cardiovascular disease, including cerebrovascular illness. * amnestic or clinical signs of current mental illness. * amnestic or clinical signs of current substance or drug abuse. * amnestic or clinical signs of any illness the responsible doctor considers relevant for participation in the study.